(S1 (S (S (NP (JJ Recombinant) (JJ human) (NN prothrombin) (NN kringle-2)) (VP (VBZ inhibits) (NP (NP (NN B16F10) (NN melanoma)) (NN metastasis)) (PP (IN through) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN neovascularization)))) (CC and) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN matrix) (NN metalloproteinase)) (NN expression)))))))) (. .)))
(S1 (S (S (NP (NP (NN Angiogenesis)) (, ,) (NP (NP (DT a) (JJ multi-step) (NN process)) (SBAR (WHNP (WDT which)) (S (VP (VBZ involves) (NP (NP (JJ endothelial) (NN cell) (NN proliferation)) (, ,) (NP (NN adhesion)) (, ,) (NP (NN migration)) (, ,) (CC and) (NP (NP (NN basement) (NN membrane)) (PRN (-LRB- -LRB-) (NP (NN BM)) (-RRB- -RRB-))) (NP (NN degradation))))))) (, ,)) (VP (VBZ is) (ADJP (JJ essential) (PP (IN for) (NP (NN tumor) (NN metastasis)))))) (. .)))
(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (JJ recombinant) (JJ human) (NN prothrombin) (NN kringle-2)) (PRN (-LRB- -LRB-) (NP (NN rk-2)) (-RRB- -RRB-))) (VP (VP (VBD inhibited) (NP (JJ bovine) (NN capillary) (JJ endothelial) (NN cell) (NN migration)) (PP (IN with) (NP (NP (NP (DT an) (NN IC-LRB-50-RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NN concentration)) (PP (IN for) (NP (NN half) (JJ maximal) (NN inhibition)))) (-RRB- -RRB-))) (PP (IN of) (NP (CD 38) (NN nM)))))) (CC and) (VP (VBD inhibited) (NP (NN adhesion)) (PP (TO to) (NP (JJ extracellular) (NN matrix) (-LRB- -LRB-) (NN ECM) (-RRB- -RRB-) (NNS proteins)))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN tumor) (NN metastasis)) (VP (VBZ requires) (NP (NN angiogenesis))))) (, ,) (NP (PRP we)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NN rk-2)) (VP (MD could) (VP (VB inhibit) (NP (NP (NNS metastases)) (VP (VBN induced) (PP (IN by) (NP (NP (NN injection)) (PP (IN of) (NP (NN B16F10) (NN melanoma) (NNS cells))) (PP (IN into) (NP (NNS mice))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD revealed) (SBAR (IN that) (S (S (NP (NP (DT the) (JJ metastatic) (NNS tumors)) (PP (IN in) (NP (NN mouse) (NN lung)))) (VP (VBD were) (VP (ADVP (RB markedly)) (VBN decreased) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner)))))) (CC and) (S (NP (NP (JJ acute) (NN lung) (NN injury)) (VP (VBN induced) (PP (IN by) (NP (NN B16F10) (NN melanoma) (NN metastasis))))) (VP (VBD was) (VP (VBN diminished) (PP (IN by) (NP (JJ systemic) (NN rk-2) (NN treatment)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ immunohistochemical) (NN analysis))) (, ,) (NP (NN rk-2)) (VP (VBD reduced) (NP (NP (NP (NN expression)) (PP (IN of) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (DT a) (JJ potent) (JJ angiogenic) (NN activator)))))))) (CC and) (NP (NP (NN neovascularization)) (PP (IN in) (NP (DT the) (NN mouse) (NN lung))))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (, ,) (NP (NN rk-2)) (VP (VBD diminished) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN matrix) (NN metalloproteinase-2)) (CC and) (NP (NN -9)))) (PP (IN in) (NP (NP (DT the) (NN mouse) (NN lung)) (SBAR (WHNP (WDT which)) (S (VP (VBZ induces) (NP (NP (NN tumor) (NN metastasis)) (CC and) (NP (NN angiogenesis))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN B16F10) (NN melanoma) (NN metastasis))) (PP (IN by) (NP (NN rk-2)))) (VP (VBD was) (VP (VBN caused) (PP (IN by) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN neovascularization)))) (CC and) (NP (NP (NN reduction)) (PP (IN of) (NP (NP (NN matrix) (NN metalloproteinase)) (NN expression)))))))))))) (. .)))
